Intravesical administration of RC48‐ADC demonstrates promising antitumor efficacy in human bladder cancer cells expressing HER2 in vivo, and it is also well tolerated with no detectable local or systemic toxicities at the therapeutic dose. This evidence concerns the gene ERBB2 and urinary bladder cancer.